The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis.
Koji Sasaki
No relevant relationships to disclose
Jason R. Gotlib
No relevant relationships to disclose
Ruben A. Mesa
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Jorge E. Cortes
No relevant relationships to disclose
Patrick Francis Kelly
Employment or Leadership Position - Infinity Pharmaceuticals
Stock Ownership - Infinity Pharmaceuticals
Jeffrey Lorne Kutok
Employment or Leadership Position - Infinity Pharmaceuticals
Stock Ownership - Infinity Pharmaceuticals
Hagop M. Kantarjian
No relevant relationships to disclose
Srdan Verstovsek
Research Funding - Infinity Pharmaceuticals